Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR 1,250.00
-19.00 (-1.50%)
Oct 23, 2026, 1:50 PM IST
Alivus Life Sciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 153,424 | 119,386 | 132,481 | 95,161 | 48,141 | 56,215 | |
Market Cap Growth | 35.29% | -9.88% | 39.22% | 97.67% | -14.36% | - |
Enterprise Value | 146,167 | 113,462 | 128,178 | 90,913 | 44,570 | 52,405 |
Last Close Price | 1269.00 | 969.24 | 1071.60 | 769.79 | 376.31 | 407.07 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 25.49 | 21.15 | 27.28 | 20.21 | 10.31 | 13.43 |
Forward PE | 22.26 | 19.63 | 23.14 | 16.54 | 9.96 | 11.60 |
PS Ratio | 6.01 | 4.68 | 5.55 | 4.17 | 2.23 | 2.65 |
PB Ratio | 4.67 | 3.58 | 4.70 | 4.08 | 2.25 | 2.74 |
P/TBV Ratio | 4.72 | 3.62 | 4.74 | 4.11 | 2.27 | 2.75 |
P/FCF Ratio | 60.29 | 46.21 | 58.79 | 33.44 | 33.62 | 12.08 |
P/OCF Ratio | 27.55 | 21.12 | 33.84 | 23.01 | 15.73 | 9.41 |
PEG Ratio | - | 1.78 | 1.45 | 1.12 | 0.98 | 0.72 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 5.73 | 4.45 | 5.37 | 3.98 | 2.06 | 2.47 |
EV/EBITDA Ratio | 17.72 | 14.41 | 18.88 | 13.59 | 6.97 | 8.53 |
EV/EBIT Ratio | 19.60 | 15.71 | 20.55 | 14.61 | 7.42 | 9.05 |
EV/FCF Ratio | 57.48 | 43.92 | 56.88 | 31.95 | 31.12 | 11.26 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.07 | 0.07 | 0.08 | 0.03 | 0.03 | 0.00 |
Debt / FCF Ratio | - | 0.22 | 0.25 | 0.06 | 0.14 | 0.01 |
Net Debt / Equity Ratio | -0.22 | -0.22 | -0.17 | -0.12 | -0.12 | -0.25 |
Net Debt / EBITDA Ratio | -0.87 | -0.92 | -0.72 | -0.42 | -0.41 | -0.83 |
Net Debt / FCF Ratio | - | -2.81 | -2.18 | -1.00 | -1.85 | -1.09 |
Asset Turnover | - | 0.69 | 0.76 | 0.82 | 0.84 | 0.95 |
Inventory Turnover | - | 1.67 | 1.69 | 1.64 | 1.87 | 2.07 |
Quick Ratio | - | 3.72 | 3.31 | 2.64 | 2.34 | 3.10 |
Current Ratio | - | 5.22 | 4.97 | 4.37 | 3.73 | 4.60 |
Return on Equity (ROE) | - | 18.36% | 18.86% | 21.07% | 22.28% | 29.83% |
Return on Assets (ROA) | - | 12.21% | 12.45% | 14.01% | 14.52% | 16.20% |
Return on Invested Capital (ROIC) | 21.90% | 22.01% | 21.18% | 23.67% | 26.11% | 27.58% |
Return on Capital Employed (ROCE) | - | 20.80% | 21.20% | 25.80% | 27.20% | 27.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.92% | 4.73% | 3.67% | 4.95% | 9.70% | 7.45% |
FCF Yield | 1.66% | 2.16% | 1.70% | 2.99% | 2.97% | 8.28% |
Dividend Yield | 0.40% | 0.51% | 0.46% | 2.90% | 5.34% | 4.58% |
Payout Ratio | 10.20% | 10.87% | - | 58.55% | 82.64% | 30.73% |
Buyback Yield / Dilution | -0.04% | -0.08% | -0.17% | -0.13% | -4.25% | -9.03% |
Total Shareholder Return | 0.36% | 0.44% | 0.30% | 2.77% | 1.10% | -4.45% |